Kiora Pharmaceuticals, Inc. (KPRX)
NASDAQ: KPRX · Real-Time Price · USD
3.270
+0.050 (1.55%)
Dec 20, 2024, 4:00 PM EST - Market closed
Kiora Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 16.02 | - | - | - | 0.01 | 2.69 | Upgrade
|
| Revenue Growth (YoY) | - | - | - | - | -99.55% | 62.54% | Upgrade
|
| Cost of Revenue | 4.83 | 4.03 | 3.45 | 5.35 | 3.27 | 4.89 | Upgrade
|
| Gross Profit | 11.19 | -4.03 | -3.45 | -5.35 | -3.26 | -2.2 | Upgrade
|
| Selling, General & Admin | 5.1 | 4.66 | 7.28 | 5.22 | 4.24 | 4.41 | Upgrade
|
| Operating Expenses | 5.1 | 4.66 | 7.28 | 5.22 | 4.24 | 4.41 | Upgrade
|
| Operating Income | 6.09 | -8.69 | -10.73 | -10.57 | -7.51 | -6.61 | Upgrade
|
| Interest Expense | -0.01 | -0.01 | -0.01 | -0.01 | -0 | -0 | Upgrade
|
| Interest & Investment Income | 0.86 | 0.17 | 0.06 | 0 | 0.02 | 0.11 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.14 | 0.03 | -1.44 | - | - | - | Upgrade
|
| EBT Excluding Unusual Items | 6.81 | -8.5 | -12.12 | -10.58 | -7.49 | -6.5 | Upgrade
|
| Merger & Restructuring Charges | - | - | - | -0.1 | -0.41 | - | Upgrade
|
| Impairment of Goodwill | - | - | - | -4.04 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.03 | -0.03 | 0 | - | 0.11 | - | Upgrade
|
| Other Unusual Items | 0.87 | -1.99 | -1.58 | 0.75 | 0.94 | -0.5 | Upgrade
|
| Pretax Income | 5.64 | -12.42 | -13.7 | -13.96 | -6.85 | -7 | Upgrade
|
| Income Tax Expense | 0.09 | 0.09 | -0.11 | -0.19 | 0.01 | 0.1 | Upgrade
|
| Earnings From Continuing Operations | 5.55 | -12.51 | -13.58 | -13.77 | -6.86 | -7.1 | Upgrade
|
| Net Income | 5.55 | -12.51 | -13.58 | -13.77 | -6.86 | -7.1 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | 0.53 | - | - | - | - | Upgrade
|
| Net Income to Common | 5.55 | -13.04 | -13.58 | -13.77 | -6.86 | -7.1 | Upgrade
|
| Shares Outstanding (Basic) | 3 | 1 | 0 | 0 | 0 | - | Upgrade
|
| Shares Outstanding (Diluted) | 3 | 1 | 0 | 0 | 0 | - | Upgrade
|
| Shares Change (YoY) | 789.70% | 561.21% | 203.73% | 110.04% | - | - | Upgrade
|
| EPS (Basic) | 1.83 | -24.25 | -166.94 | -514.04 | -538.01 | - | Upgrade
|
| EPS (Diluted) | 1.69 | -24.25 | -166.94 | -514.04 | -538.01 | - | Upgrade
|
| Free Cash Flow | 8.18 | -9.56 | -10.43 | -10.74 | -7.34 | -8.15 | Upgrade
|
| Free Cash Flow Per Share | 2.49 | -17.76 | -128.16 | -400.88 | -575.29 | - | Upgrade
|
| Gross Margin | 69.86% | - | - | - | - | -82.03% | Upgrade
|
| Operating Margin | 38.05% | - | - | - | -62238.67% | -246.06% | Upgrade
|
| Profit Margin | 34.64% | - | - | - | -56901.65% | -264.21% | Upgrade
|
| Free Cash Flow Margin | 51.05% | - | - | - | -60844.56% | -303.57% | Upgrade
|
| EBITDA | 6.12 | -8.64 | -10.69 | -10.53 | -7.47 | -6.56 | Upgrade
|
| EBITDA Margin | 38.18% | - | - | - | - | -244.13% | Upgrade
|
| D&A For EBITDA | 0.02 | 0.05 | 0.04 | 0.05 | 0.03 | 0.05 | Upgrade
|
| EBIT | 6.09 | -8.69 | -10.73 | -10.57 | -7.51 | -6.61 | Upgrade
|
| EBIT Margin | 38.05% | - | - | - | - | -246.06% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.